Harris Scott Matthew's Insider Trades & SAST Disclosures
Harris Scott Matthew's most recent trade in Altimmune Inc was a trade of 67,787 Common Stock, par value $0.0001 done . Disclosure was reported to the exchange on March 7, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Harris Scott Matthew.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Mar 2025 | 67,787 | 14,069 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 9,275 | 18,550 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 9,275 | 74,000 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 7,775 | 7,775 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 7,775 | 84,564 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 6,166 | 78,898 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 6,166 | 0 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.00 per share. | 30 Jan 2025 | 3,173 | 70,827 (0%) | 0% | 7 | 22,211 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.64 per share. | 30 Jan 2025 | 2,708 | 81,856 (0%) | 0% | 6.6 | 17,981 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.64 per share. | 30 Jan 2025 | 2,109 | 76,789 (0%) | 0% | 6.6 | 14,004 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 5.18 per share. | 30 Jan 2025 | 1,905 | 72,732 (0%) | 0% | 5.2 | 9,868 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2025 | 183,600 | 183,600 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2025 | 63,400 | 63,400 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2025 | 14,600 | 69,719 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2025 | 14,600 | 43,800 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.98 per share. | 25 Jan 2025 | 4,994 | 64,725 (0%) | 0% | 7.0 | 34,858 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 5.41 per share. | 31 Jul 2024 | 1,486 | 55,119 (0%) | 0% | 5.4 | 8,039 | Common Stock, par value $0.0001 |
| Altimmune Inc | Harris Scott Matthew | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 7,775 | 55,965 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Harris Scott Matthew | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 7,775 | 15,550 | - | - | Restricted Stock Units | |
| Altimmune Inc | Harris Scott Matthew | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 6,166 | 6,166 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Harris Scott | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 6,166 | 49,991 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Harris Scott | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.32 per share. | 01 Feb 2024 | 2,332 | 53,633 (0%) | 0% | 9.3 | 21,734 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Harris Scott | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.88 per share. | 01 Feb 2024 | 1,801 | 48,190 (0%) | 0% | 9.9 | 17,794 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 9,275 | 43,277 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Harris Scott | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 9,275 | 27,825 | - | - | Restricted Stock Units | |
| Altimmune Inc | Scott Matthew Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 2.69 per share. | 30 Jan 2024 | 3,257 | 43,825 (0%) | 0% | 2.7 | 8,761 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.80 per share. | 30 Jan 2024 | 2,709 | 40,568 (0%) | 0% | 9.8 | 26,548 | Common Stock, par value $0.0001 |
| Altimmune Inc | Harris Scott Matthew | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 163,200 | 163,200 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Harris Scott Matthew | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 58,400 | 58,400 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 2.81 per share. | 31 Jul 2023 | 691 | 34,002 (0%) | 0% | 2.8 | 1,942 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 4.22 per share. | 23 Mar 2023 | 10,000 | 33,311 (0%) | 0% | 4.2 | 42,200 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 7,775 | 23,325 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 7,775 | 25,675 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.04 per share. | 02 Feb 2023 | 2,364 | 23,311 (0%) | 0% | 15.0 | 35,555 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 6,166 | 20,083 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 6,166 | 12,332 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.78 per share. | 31 Jan 2023 | 2,183 | 17,900 (0%) | 0% | 13.8 | 30,082 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 10.21 per share. | 31 Jan 2023 | 1,296 | 13,917 (0%) | 0% | 10.2 | 13,230 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 105,000 | 105,000 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 37,100 | 37,100 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 6.86 per share. | 31 Jul 2022 | 1,076 | 12,621 (0%) | 0% | 6.9 | 7,381 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.52 per share. | 28 Feb 2022 | 30,000 | 11,545 (0%) | 0% | 7.5 | 225,600 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 30,000 | 31,400 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.92 per share. | 28 Feb 2022 | 30,000 | 41,545 (0%) | 0% | 1.9 | 57,639 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 91,600 | 91,600 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 31,100 | 31,100 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 6,166 | 18,498 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 6,166 | 13,728 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.98 per share. | 31 Jan 2022 | 2,183 | 11,545 (0%) | 0% | 8.0 | 17,420 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 6.86 per share. | 31 Jan 2022 | 1,800 | 7,562 (0%) | 0% | 6.9 | 12,348 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 7.71 per share. | 31 Jul 2021 | 725 | 5,762 (0%) | 0% | 7.7 | 5,589 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 90,000 | 90,000 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 24,664 | 24,664 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 12.14 per share. | 31 Jan 2021 | 968 | 5,037 (0%) | 0% | 12.1 | 11,752 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Director | Sale of securities on an exchange or to another person at price $ 10.02 per share. | 12 Nov 2020 | 4,015 | 4,069 (0%) | 0% | 10.0 | 40,230 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 1.46 per share. | 31 Jul 2020 | 8,084 | 8,084 (0%) | 0% | 1.5 | 11,803 | Common Stock, par value $0.0001 |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges